Home › NDC Lookup › RxCUI directory › RxCUI 2049271

Pimavanserin 10 MG Oral Tablet [Nuplazid] — RxCUI 2049271

RxNorm drug concept · Semantic branded drug
RxCUI 2049271 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2049271
Official namePimavanserin 10 MG Oral Tablet [Nuplazid]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asNuplazid 10 MG Oral Tablet; pimavanserin 10 mg (as pimavanserin tartrate 11.8 MG) Oral Tablet [Nuplazid]
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)2,158 prescriptions · 20 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Pimavanserin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Pimavanserin is specifically approved to treat hallucinations and delusions that happen as part of Parkinson's disease psychosis — so things like seeing or hearing things that aren...
  • Yes — both Nuplazid capsules and the generic pimavanserin capsules can be opened and the powder sprinkled over a tablespoon of soft food like applesauce, yogurt, or pudding, or sti...
  • Can I open the capsule if I have trouble swallowing it?
  • The most common ones are leg or foot swelling and feeling confused or disoriented. Nausea, constipation, and unsteady walking can also happen. The more serious thing to watch for i...
📖 Read our full Pimavanserin guide →

🕸️ Concept Web — How Pimavanserin 10 MG Oral Tablet [Nuplazid] Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Pimavanserin 10 MG Oral Tablet [Nuplazid] RxCUI 2049271

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Pimavanserin 1791685
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Nuplazid 1791692
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Pimavanserin Oral Tablet 1791690
    • Pimavanserin Oral Product 1791688
    • Pimavanserin Pill 1791689
    • Pimavanserin Oral Tablet [Nuplazid] 1791694
    • Nuplazid Oral Product 1791695
    • Nuplazid Pill 1791696
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Pimavanserin 10 MG Oral Tablet SCD · 2049269
  • Pimavanserin 10 MG SCDC · 2049268
  • Pimavanserin Oral Tablet SCDF · 1791690
  • Pimavanserin Oral Product SCDG · 1791688
  • Pimavanserin Pill SCDG · 1791689

Brand-Name Concepts

  • Pimavanserin 10 MG [Nuplazid] SBDC · 2049270
  • Pimavanserin Oral Tablet [Nuplazid] SBDF · 1791694
  • Nuplazid Oral Product SBDG · 1791695
  • Nuplazid Pill SBDG · 1791696
  • Nuplazid BN · 1791692

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2049271 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
63090-0100-30 30 TABLET, COATED in 1 BOTTLE, PLASTIC (63090-100-30) NUPLAZID Acadia Pharmaceuticals Inc. 2018-06-28
63090-0340-30 30 CAPSULE in 1 BOTTLE, PLASTIC (63090-340-30) NUPLAZID Acadia Pharmaceuticals Inc. 2018-06-28
Observed labelers: Acadia Pharmaceuticals Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.